Glycomed Inc. said it has received notice of allowance for a U.S.patent that will cover use of its Galardin compound to treatcorneal ulcers.
Last week the Alameda, Calif., company (NASDAQ:GLYC)announced it had won an orphan drug designation for Galardinand expects to file in mid-1992 to start clinical trials. The eye-drop drug will be the company's first product to enter humantrials.
The stock closed at $24, up $1.25, on Wednesday.
(c) 1997 American Health Consultants. All rights reserved.